Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Mycobacterial Tenosynovitis After Sea Urchin Spine Injury in an Immunocompromised Patient.

Vargas CR, Kanwar A, Dousa KM, Skalweit MJ, Rowe D, Gatherwright J.

Open Forum Infect Dis. 2018 Nov 2;5(11):ofy285. doi: 10.1093/ofid/ofy285. eCollection 2018 Nov. No abstract available.

2.

Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection.

Dousa KM, Babiker A, Van Aartsen D, Shah N, Bonomo RA, Johnson JL, Skalweit MJ.

Open Forum Infect Dis. 2018 Jul 18;5(7):ofy168. doi: 10.1093/ofid/ofy168. eCollection 2018 Jul.

4.

An unusual case of underlying rilpivirine resistance in an antiretroviral-naïve man with AIDS.

Skalweit MJ.

Int J STD AIDS. 2016 Dec;27(14):1346-1349. Epub 2016 Apr 12.

PMID:
27074792
5.

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.

Skalweit MJ.

Drug Des Devel Ther. 2015 Jun 4;9:2919-25. doi: 10.2147/DDDT.S61436. eCollection 2015. Review.

6.

Effect of asparagine substitutions in the YXN loop of a class C β-lactamase of Acinetobacter baumannii on substrate and inhibitor kinetics.

Skalweit MJ, Li M, Taracila MA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1472-7. doi: 10.1128/AAC.03537-14. Epub 2014 Dec 22.

7.

A rare case of immune reconstitution inflammatory syndrome presenting as secondary syphilis.

Khatri A, Skalweit MJ.

Int J STD AIDS. 2015 Sep;26(10):749-51. doi: 10.1177/0956462414553013. Epub 2014 Oct 13.

PMID:
25311145
8.

N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.

Skalweit MJ, Li M, Conklin BC, Taracila MA, Hutton RA.

Antimicrob Agents Chemother. 2013 Apr;57(4):1596-602. doi: 10.1128/AAC.01334-12. Epub 2013 Jan 14.

9.

Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Li M, Conklin BC, Taracila MA, Hutton RA, Skalweit MJ.

Antimicrob Agents Chemother. 2012 Nov;56(11):5678-86. doi: 10.1128/AAC.00711-12. Epub 2012 Aug 20.

10.

Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Papp-Wallace KM, Senkfor B, Gatta J, Chai W, Taracila MA, Shanmugasundaram V, Han S, Zaniewski RP, Lacey BM, Tomaras AP, Skalweit MJ, Harris ME, Rice LB, Buynak JD, Bonomo RA.

Antimicrob Agents Chemother. 2012 Nov;56(11):5687-92. doi: 10.1128/AAC.01027-12. Epub 2012 Aug 20.

11.

The importance of the trans-enamine intermediate as a β-lactamase inhibition strategy probed in inhibitor-resistant SHV β-lactamase variants.

Ke W, Rodkey EA, Sampson JM, Skalweit MJ, Sheri A, Pagadala SR, Nottingham MD, Buynak JD, Bonomo RA, van den Akker F.

ChemMedChem. 2012 Jun;7(6):1002-8. doi: 10.1002/cmdc.201200006. Epub 2012 Mar 21.

12.

Penicillin sulfone inhibitors of class D beta-lactamases.

Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA.

Antimicrob Agents Chemother. 2010 Apr;54(4):1414-24. doi: 10.1128/AAC.00743-09. Epub 2010 Jan 19.

13.

Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Endimiani A, Doi Y, Bethel CR, Taracila M, Adams-Haduch JM, O'Keefe A, Hujer AM, Paterson DL, Skalweit MJ, Page MG, Drawz SM, Bonomo RA.

Biochemistry. 2010 Feb 9;49(5):1014-23. doi: 10.1021/bi9015549.

14.

SAME is different: a case report and literature review of Staphylococcus aureus metastatic endophthalmitis.

Nixdorff NA, Tang J, Mourad R, Skalweit MJ.

South Med J. 2009 Sep;102(9):952-6. doi: 10.1097/SMJ.0b013e3181b21a40. Review.

PMID:
19668027

Supplemental Content

Loading ...
Support Center